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Abstract 
Background. Detection of isolated tumour cells (ITC) in the blood or minimal deposits in distant organs such 
as bone marrow (BM) could be important to identify breast cancer patients at high risk of relapse or disease 
progression. PCR amplification of tissue or tumour selective mRNA is the most powerful analytical tool for 
detection of this micrometastasis. We have evaluated for the first time, the diagnostic accuracy of small breast 
epithelial mucin (SBEM) as a potential marker for BM micrometastasis in breast cancer. 
Methods. A nested RT-PCR assay for detection of SBEM mRNA was compared with immunocytochemistry 
(ICC) with anticytokeratin AE1/AE3 antibody in paired samples obtained from the BM of breast cancer 
patients. Associations of SBEM mRNA detection in BM and clinical and pathological parameters were 
evaluated. SBEM mRNA status and time to breast cancer progression were analysed using Kaplan–Meyer 
curves. 
Results. Fifty stages I–IV breast cancer female patients were prospectively included in our study. SBEM 
specific transcript was found in BM in 26% of the patients. Detection rate was similar to the percentage of 
patients with ITCs detected using ICC (24%). SBEM mRNA in BM aspirates were significantly associated 
with presence of clinically active disease, including locally advanced and metastatic patients (47%, 
P = 0.021) and tumours with positive hormonal receptors (36.7%, P = 0.035). In addition association with 
Her2/neu over-expression (44.4%, P = 0.051) and low proliferating tumours (36%, P = 0.067) were close to 
significant levels. When we analysed time to breast cancer progression adjusting for grade or hormone 
receptor status, presence of SBEM mRNA in BM defines distinct prognostic groups. 
Conclusions. SBEM might represent a suitable marker for molecular detection of ITCs in BM in breast cancer 
patients. Analysis of prognostic value for SBEM mRNA-based assay should take into account the 
heterogeneity and different molecular subtypes of breast cancer. 
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Introduction 
Breast cancer is the most common type of cancer in European women, accounting for 429,900 
cases in 2006 (Ferlay et al. 2007). Relative survival from breast cancer in women has improved 
steadily in all European countries in recent years. However age-standardized 5-year relative 
survival remains within a range of 78.1–80% (Verdecchia et al. 2007). Metastatic haematogenous 
spreading is one of the most important factors affecting the prognosis of carcinoma patients, 
including breast cancer. Circulating tumour cells and occult metastasis (micrometastasis) are 
considered early events in the progression of breast cancer. Detection of carcinoma cells in the 
blood or minimal deposits in distant organs such as bone marrow (BM) could be important to 
identify patients at high risk of relapse or disease progression (Pantel and Alix-Panabieres 2007). 
A pooled analysis of data from different clinical studies found strong evidence that the presence of 
isolated tumour cells (ITC) in BM by means of immunocytochemical-based detection is associated 
with a poor prognosis in stage I–III breast cancer patients (Braun et al. 2005). 
 
As stated previously, immunocytochemistry (ICC) with anticytokeratin (CK) antibodies would 
be considered as a benchmark technique for ITC detection. Thus, studies evaluating molecular 
methods of ITC detection and novel markers would be performed in comparison with standardized 
ICC (Braun and Naume 2005). PCR amplification of tissue or tumour selective mRNA is the most 
powerful analytical tool for detection of this circulating or micrometastatic cells. Cytokeratins and 
mammaglobin are among the most frequent mRNA markers used in different reverse transcriptase-
polymerase chain reaction (RT-PCR) assays in breast cancer patients. However down-regulation 
of mRNA marker in tumour cells (Woelfle et al. 2003) or low-level transcription of selected 
targets in the haematopoietic compartment (Kruger et al. 2001) could compromise both sensitivity 
and specificity of molecular methods. 
 
The selection of novel breast-specific transcripts and the development of multi-marker RT-
PCR assays are clearly outstanding research questions. In this context we have evaluated the 
diagnostic accuracy of small breast epithelial mucin (SBEM) as a potential marker for BM 
micrometastasis in breast cancer. The SBEM gene (GenBank No. AF414087] was identified by 
Miksicek et al. (2002) using the cDNA xProfiler tool. SBEM product is similar to proteins B511 s 
(Houghton et al. 2001) and BS106 (Colpitts et al. 2002). The SBEM gene is predicted to code for a 
low molecular weight glycoprotein with highly similarity to sialomucins, including MUC1. Thus 
the SBEM gene is also known as Mucin-like 1 gene (GeneID: 118430). However SBEM gene has 
shown more specific patterns of expression, limited to breast and salivary glands. 
 
Using an in silico approach (Ayerbes et al. 2008) we have analysed the expression of SBEM 
tags in a series of human breast carcinomas SAGE libraries. In addition we developed a model 
system based on RT-PCR for SBEM mRNA to detect isolated breast tumour cells. Using SBEM 
nested approach we could detect up to one cancer cell among 1 μg of normal BM RNA, similar to 
the results obtained with mammaglobin (hMAM) mRNA amplification. No significant expression 
for SBEM was found in haematopoietic cell-lines neither in 23 controls BM analysed. 
 
The aim of our study was to compare directly the detection rate of ITC in BM by SBEM RT-
PCR and ICC. Molecular assay for detection of SBEM mRNA in BM of breast cancer patients was 
compared with a benchmark technique of disseminated tumour cell detection as ICC with 
anticytokeratin AE1/AE3 antibody. Exploratory analysis included associations of SBEM mRNA 
detection in BM and clinical and pathological parameters. In addition SBEM mRNA status in BM 




Consecutive female breast cancer outpatients were included from the medical oncology unit at 
University hospital in La Coruña, Spain. Inclusion criteria were: Confirmed pathologic diagnosis 
of invasive breast cancer; stage I–III with no prior systemic therapy for breast cancer; stage IV 
patients with no previous systemic therapy or in confirmed progression after such treatment; 
written informed consent. Exclusion criteria were defined as: previous invasive epithelial cancer; 
coagulopathies or thrombopenia (<20,000); any previous systemic therapy for breast cancer except 
stage IV patients with confirmed progressive disease; prior pelvic radiation; previous 
diphosphonate therapy. 
 
The diagnostic work-up included clinical examination, blood sampling with CA 15.3 and CEA 
serum determination, mammography, chest x-ray, abdominal ultrasound and bone scan. Computed 
tomography scanning of the chest, abdomen and pelvis was performed on stage IV patients. 
 
After informed, written consent, BM aspiration was performed under local anaesthesia, just 
before systemic treatment for pathological confirmed breast cancer. In patients who first 
underwent surgery as loco-regional treatment for primary disease, BM aspirate was obtained at 
least 2–3 weeks after operation but before 8 weeks. Otherwise BM samples were obtained before 
neo-adjuvant chemotherapy or in presence of active metastatic disease. BM was aspirated from 
anterior or posterior iliac crest unilaterally. Skin incision was made to avoid contamination with 
epidermal cells. 
 
The study was approved by the Institutional Review Board of the Ethic Committee of Clinical 
Investigation of Galicia (Spain) and written informed consent was obtained from all patients. 
Analysis of primary tumour and axillary lymph nodes 
The primary tumour and axillaries lymph nodes collected during surgery were processed on a 
routine diagnostic basis. Histological tumour type, tumour size and nodal involvement were 
analysed, and the disease was staged according to the TNM system (American Joint Committee on 
Cancer, AJCC. 5ª edition). Tumour grading was performed according to modified Bloom–
Richardson score. Tumour tissue immunostainings were performed using mouse monoclonal 
antibodies (mAb) against oestrogen receptor (ER) and progesterone receptor (PgR); clones ER-
6F11/2 and PGR-312, respectively; Novocastra, Ki-67 antigen (MIB-1, DAKO) and rabbit 
polyclonal antibody against Her2/neu (DAKO). Immunopositivity was recorded if ≥ 10% (ER, 
PgR) of the nucleus of tumour cells were immunostained. In addition, Her2/neu required distinct 
membranous staining for being considered positive. 
Preparation of the bone marrow 
Unilateral BM aspiration was performed from anterior or posterior iliac crests under local 
anaesthesia and transferred into heparinized tubes. One aliquot of one-third and at least 1 ml was 
used for mRNA isolation. Two-thirds were subjected to mononuclear cell (MNC) separation by 
density centrifugation using Lymphoprep (Nycomed, Oslo, Norway). MNCs were collected from 
the interphase layer and washed twice in PBS (Life Technologies, Inc.) with 10% FCS. Cytospins 
were prepared (5 × 10
5
 MNCs/slide) on polylysine-coated slides in a Hettich cytocentrifuge. The 
cytospins were air-dried at RT overnight before freezing at −80°C or immunostaining. 
 
Bone marrow aliquots destined to mRNA extraction were stabilized immediately after 
aspiration with the guanidinium lysis buffer RNA/DNA Stabilization Reagent for Blood/BM 
(Roche) at 10% (vol/vol). Immediate stabilization of the sample using a commercial reagent 
effectively protects mRNA, avoids loss of target mRNA and ensures higher reproducibility in 
clinical samples. Furthermore, sedimentation of all tumour cells in the mononuclear fraction (as 
needed for ICC analysis) is not warranted by density centrifugation (Choesmel et al. 2004). 
 
Bone marrow lysates were stored at −80°C until mRNA isolation. The mRNA isolation 
procedure was performed using mRNA Isolation Kit for Blood/BM (Roche) following 
manufacturer’s instructions. Briefly, total nucleic acid fraction was adsorbed to magnetic glass 
particles and poly (A) + RNA was captured by using biotin-labelled oligo(dT) and streptavidin-
coated magnetic particles. Elution was performed on each mRNA preparation in 12 μl RNase-free 
redistilled water. Purified poly (A) + RNA was further processed in RT-PCR or stored at −80°C 
until use. 
Immunocytochemical staining 
Immunocytochemical staining was performed using the Vectastain ABC-AP kit (VECTOR) 
following manufacturer’s procedure. Slides (5 × 105 BM MNCs) were incubated with the anti-
cytokeratin mAbs AE1/AE3 (DAKO). At least two slides were incubated with a negative control 
antibody of the same immunoglobulin isotype (IgG1). The visualization stage included Vector Red 
alkaline phosphatase substrate kit. Endogenous alkaline phosphatase activity was inhibited by 
addition of levamisole. The slides were counterstained with Gills’s haematoxylin to visualize 
nuclear morphology. The slides were manually screened by light microscopy by one of the 
pathologists (PID) with no knowledge about clinical data or RT-PCR status. All of the stained 
cells were closely evaluated. Categorization of CK immunopositive cells was performed according 
to the recommended guidelines (Borgen et al. 1999). Presence of micrometastasis was recorded as 
positive when stained cells shown typical tumour cell morphology or when these immunostained 
cells lacked haematopoietic characteristics and were not found in negative controls. 
RNA isolation and RT-PCR 
The mRNA isolation procedure was performed using mRNA Isolation Kit for Blood/BM 
(Roche) following manufacturer’s instructions. Briefly, total nucleic acid fraction was adsorbed to 
magnetic glass particles and poly(A) + RNA was captured by using biotin-labelled oligo(dT) and 
streptavidin-coated magnetic particles. Elution was performed on each mRNA preparation in 12 μl 
RNase-free redistilled water. Purified poly (A) + RNA was further processed in RT-PCR or stored 
at −80°C until use. 
 
The reverse transcription was performed using the SuperScript II First-Strand Synthesis 
System for RT-PCR (Invitrogen) using random hexamers according to manufacturer’s 
instructions. PCR amplifications were carried out with AmpliTaq Gold PCR Master Mix (Applied 
Biosystems). First round PCR amplification of SBEM mRNA was performed using specific 
primers (SBEM-U-O and SBEM-L-O described by Miksicek et al. (2002). In the nested-PCR new 
primer pairs (SBEM-S-I 5′TGA TCT TCA GGT CAC CAC CA3′ and SBEM-A-I 5′TGG ATA 
CGT GTC AGC TGG AG3′) were used, designed using software available on the Internet (Rozen 
and Skaletsky 2000). The gene and mRNA structure of SBEM and primers are shown in Fig. 1, 





Fig. 1. Small breast epithelial mucin gene diagram and primers. The SBEM gene maps on chromosome 12, at 12q13. It 
contains five introns and four exons. Transcription produces four (a–d) alternatively spliced mRNAs. Designed primers for 
RT-PCR are shown 
First round PCR was performed in 50 μl of reaction mixture containing 2 μl of template cDNA, 
deionized water, outer SBEM primers U and L, 1 μl 20 μM of each, and PCR Master Mix (2X) 
25 μl. In SBEM nested reaction 1 μl of first round PCR template and 0.5 μl at 20 μM of each inner 
SBEM primer pair were used. For first round SBEM PCR amplification, an initial activation at 
95°C was used for 5 min, followed by 35 cycles of 95°C (30 s), 54°C (1 min) and 72°C (1 min). 
Finally, the last extension was at 72°C for 7 min. For SBEM nested reaction, an initial activation at 
95°C for 2 min was used, followed by 20 cycles of 95°C 40 s, 62°C 15 s and 72°C 20 s. Last 
extension was at 72°C for 7 min. PCR products were electrophoresed through agarose gel and 
stained with 5% ethidium bromide. Beta-2 microglobulin serves as a positive control target. 
Negative controls were included in each experiment. 
DNA sequencing 
Polymerase chain reaction products were used as template DNA. Products were purified by 
enzymatic method (ExoSAP-It, Amersham USB). DNA sequencing was performed in a reference 
facility on ABI 3700 (Applied Biosystems) using Big Dye Terminators. Sense SBEM-specific 
primers were used. 
Study design and statistical analysis 
The study was designed as prospective and observational. Its primary objective was to estimate 
and compare the proportion of breast cancer patients with a positive mRNA transcript in BM with 
respect to the proportion of patients with CK-positive tumour cells in BM as a reference standard. 
Both early stage and metastatic patients were included in the study in order to estimate these 
proportions in a cohort of patients commonly found in every-day clinical practice. Detection rate 
using anti-CK antibodies is related to different variables including clinical and methodological 
parameters (Pantel et al. 1994). To obtain a power of 80% and P = 0.05 to find out differences 
using McNemar’s test with the continuity correction, sample size was calculated in 47 pairs, 
considering that CK positive cells are detected in BM in 25% of the patients, mRNA marker 
expression could be detected in 45% and an estimated 25% of discordant pairs. 
 
Exploratory analysis included associations of SBEM mRNA detection in BM and clinical and 
pathological parameters. The relationship between categorical variables was analysed by Chi-
squared test with continuity correction when applicable, or Fisher’s exact test. SBEM mRNA 
status in BM and time to breast cancer progression (TTP), defined as the period between BM 
aspirate and first recurrence, were analysed using Kaplan–Meyer curves and compared with the 
log-rank test. The joint effect of covariables was examined using the Cox proportional hazard 
regression model. P values < 0.05 were considered statistically significant. Statistical analysis was 
performed by SPSS (Version 14.0) 
Results 
Patients and clinical data 
From February 2002 to May 2003, 50 breast cancer female patients were included. Clinical 
characteristics are shown in Table 1. BM aspiration was performed after R0 surgery in 33 patients. 
In 17 patients BM samples were obtained before neo-adjuvant chemotherapy for locally advance 
disease or in presence of active metastatic disease. Thus, this subgroup of patients was 
prospectively defined to have clinically active disease at the time of BM sampling. The median 
follow-up time was 258.5 weeks (range 18–298 weeks). Breast cancer progression was detected in 
15 patients (30%). There were six relapses from stage I to III patients and nine progressions of 
metastatic disease. Progression occurred at median time of 61 weeks (range 13–248 weeks). Seven 
patients died of metastatic disease. 
  
Table 1. Clinical characteristics of the patients 
  n  % 
   
Age (years) 53.6 (± 12.18) 32–87 
 < 50 years 23 46 
 ≥ 50 years 27 54 
Stage 
 I 13 26 
 II 19 38 
 III 7 14 
 IV 11 22 
pT     
 pT1 18 36 
 pT2 19 38 
 pT3 9 18 
 pT4 4 8 
pN     
 pN0 21 42 
 pN1 25 50 
 pN2 3 6 
 pN3 1 2 
Hormonal receptors 
 Negative 20 40 
 Positive 30 60 
Histology     
 Ductal 35 70 
 Lobular 4 8 
 Other 11 22 
Her2     
 Unknown 4 8 
 0–1 25 50 
 2 4 8 
 3 17 34 
HR and Her2 negative 12 24 
Vascular invasion 
 Unknown 8 16 
 No 23 46 
 Yes 19 38 
Histological grade 
 Unknown 5 10 
 1 10 20 
 2 17 34 
 3 18 36 
Ki-67 
 Unknown 2 4 
 < 20% 25 50 
 ≥ 20% 23 46 






First round PCR amplification for SBEM mRNA in BM shows positive results in four patients 
(8%). Nested amplifications were positive in another nine patients (18%). Thus, globally, RT-PCR 
for SBEM was positive in BM in 13 out 50 breast cancer patients (26%; standard error 0.06). 
Cytokeratin immunocytochemistry 
Isolated tumour cells in BM were detected using anti-cytokeratin mAbs AE1/AE3 and 
standardized morphological criteria. At least 2 × 10
6
 BM MNC cells were screened per patient. 
BM aspirate did not obtain enough samples for immunocytochemical analysis in one patient with 
bone metastasis. Presence of ITC in BM was found in 12 patients (24%; standard error 0.06). The 
number of tumour cells detected were: one (four patients), two (two patients), three (three 
patients), six (one patient) and ten or more in two patient. 
Diagnostic accuracy of SBEM RT-PCR 
The primary objective of our study was to estimate and compare the proportion of breast 
cancer patients with a positive SBEM mRNA transcript in BM in relation to the proportion of 
patients with CK-positive tumour cells in BM as a standard reference. Results are shown in 
Table 2. RT-PCR for SBEM was positive in 26% of the patients. Presence of ITC using CK 
staining was found in 24% of the patients. According to McNemar’s test, there was no difference 
in ITC detection in BM between SBEM RT-PCR and ICC [two-tailed P value = 1 (odds ratio 
1.125; 95% confidence interval 0.385–3.351)]. The kappa value was low (0.094, P = 0.56). 
Table 2. Comparison between SBEM RT-PCR and cytokeratin immunocytochemistry for the detection of disseminated 
epithelial cells in bone marrow from breast cancer patients 
  
Cytokeratin immunocytochemistry Pa  
+ − NS 
     
SBEM mRNA in bone marrow 
+ 4 9   
− 8 29   
     
 
aMcNemar’s test 
A concordance of 66% (33 of 50; 95% CI 51.14–78.41) was found between SBEM RT-PCR 
and ICC. Sensitivity and specificity of SBEM RT-PCR, considering ICC as a reference, were 
33.3% (95% CI 11.3–64.6) and 76.32% (95% CI 59.38–87.97) respectively. 
 
Breast cancer progression was found in six patients (40 %) with SBEM mRNA in BM but only 
in two patients (13.3 %) with CK positive cells in BM. Diagnostic accuracy for SBEM RT-PCR for 
breast cancer progression was estimated in 68% (95% CI 53.2–80%). By contrast, accuracy for 
CK-ICC was only 54% (95% CI 39.5–67.9%). 
  
Correlations with clinicopathology 
Associations of BM status and clinical and pathologic characteristics of the patients are shown 
in Table 3. SBEM mRNA in BM aspirates were significantly associated with presence of clinically 
active disease (47%, P = 0.021) and tumours with positive hormonal (oestrogen and/or 
progesterone) receptors (36.7%, P = 0.035). Interestingly, association with Her2/neu 
overexpression (44.4%, P = 0.051) and low proliferating tumours, defined as nuclear Ki67 
staining < 20% (36%, P = 0.067) were nearly significant. 
  
Table 3. Associations of bone marrow status and clinicopathologic characteristics of the patients 
Characteristic 
SBEM RT-PCR positive 
 
CK-ICC positive 
Number % Significance 
 
Number % Significance 
        
Age     0.526      0.730 
 < 50 years 5 10    5 10   
 ≥ 50 years 8 16    7 14   
Stage     0.180      0.825 
 I–II 6 18.7    8 25   
 III–IV 7 38.9    4 22.2   
Active disease     0.021a       0.728 
 Yes 8 47    5 29.4   
 No 5 15.2    7 21.2   
Tumour status      0.149      0.791 
 T1-2 7 19.4    9 25   
 T3-4 6 42.8    3 21.4   
Lymph node status     0.340      0.979 
 N0 4 19.0    5 23.8   
 N+ 9 31.0    7 24.1   
Metastasis     0.126      0.609 
 M0 8 20.5    10 25.6   
 M1 5 45.5    2 18.2   
Histological grade     0.891      0.008a  
 1-2 7 25.9    2 7.4   
 3 5 27.8    8 44.4   
 Unknown 1 20    2 40   
Hormonal receptors     0.035b       0.506 
 Positive 11 36.7    6 30   
 Negative 2 10    6 20   
Her2/neu     0.051b       0.829 
 Positive 8 44.4    4 22   
 Negative 5 17.9    7 25   
 Unknown 0      1 25   
Vascular invasion      0.156      0.155 
 Positive 7 36.9    3 15.8   
 Negative 3 13.0    5 21.7   
 Unknown 3 37.5    4 50   
Ki-67 staining     0.067b       0.616 
 <20% 9 36.0    5 20   
 ≥20% 3 13    6 26.1   
 Unknown 1 50    1 50   
CA 15.3     0.719      0.928 
 ≤35 9 24.3    9 24.3   
 >35 4 30.8    3 23.1   
        
 
a P value computed by Fisher’s exact test 





Although positive results for SBEM mRNA were more frequent in patients with stage III–IV 
(38.9%), T3–T4 tumours (42.8%), positive axillaries lymph nodes (31%), presence of metastasis 
(45.5%) and vascular invasion (36.9%) these associations did not reach statistically significance. 
Presence of CK-positive tumour cells in BM was associated only with histological grade 3 
(P = 0.008). 
 
Kaplan–Meier survival analysis (Fig. 2) suggest a reduced time to breast cancer progression 
(TTP) among the SBEM mRNA BM positive patients, although this was not significant (log-rank 
test, P = 0.150). Subgroup analysis was performed (Table 4). Interestingly, when TTP was 
analysed in relation to the grade of the tumours concomitantly with the presence or absence of 
SBEM mRNA in BM, a statistically significant association was observed (long-rank test, 
P = 0.045). In addition and in spite of limited number of patients, presence of SBEM in BM 
defines a very poor prognostic group in hormonal receptors negative patients (log-rank test, 
P = 0.027). Thus, in this HR negative cohort (n = 20) the two early breast cancer patients with 




Fig. 2. Kaplan–Meier graphs for time to breast cancer progression according to SBEM mRNA status in bone marrow. 
Kaplan–Meier estimates are shown for the entire breast cancer cohort (a), positive (b) and negative (c) hormonal receptors 
and adjusted for grade (d). Symbols on the graph lines represent censored data; P-values are given for log rank tests. 
Asterisk indicates grade was unknown in five patients 
 
  
Table 4. Time to breast cancer progression and SBEM bone marrow status determined by RT-PCR: subgroup analysis 
  Bone marrow status Patients (n) 
 
Time to progression (weeks) 
 
Mean Standard error 
      
Grade 1–2 
SBEM (−) 20  246.1 20.7 
SBEM (+) 7  198.7 37.9 
Grade 3 
SBEM (−) 13  244.1 25.3 
SBEM (+) 5  154.4 44.8 
Hormonal receptors (+) 
SBEM (−) 19  249.9 18.9 
SBEM (+) 11  225.4 29.2 
Hormonal receptors (−) 
SBEM (−) 18  222.3 24.6 
SBEM (+) 2  46.5 17.5 
      
 
The effect of covariables in TTP was examined using the Cox proportional hazard regression 
model. Results are showed in Table 5. In multivariate analysis only stage at the time of BM 
aspirate was statistical significant. 
Table 5. Time to breast cancer progression in relation to clinicopathological characteristics and SBEM bone marrow status 
determined by RT-PCR: Cox proportional hazard regression model 
Variable Subset Hazard ratio (95% confidence interval) P  
 
Univariate analysis 
 Active disease No/yes 5.47 (1.86–16.08) 0.002 
 Ca 15.3 Normal/high 4.97 (1.79–13.79) 0.002 
 Stage I–II/II–IV 12.20 (3.39–43.81) 0.0001 
 Lymph Nodes Negative/positive 5.22 (1.17–23.16) 0.030 
 SBEM  Negative/positive 2.10 (0.75–5.91) 0.160 
 Grade I–II/III 1.076 (0.341–3.393) 0.9 
 Hormonal receptors Negative/positive 0.686 (0.249–1.893) 0.467 
Multivariate analysis 
 Active disease No/yes 0.26 (0.051–1.287) 0.098 
 Ca 15.3 Normal/high 3.07 (0.89–10.51) 0.074 
 Stage I–II/III–IV 16.73 (2.99–93.62) 0.001 
 Lymph nodes Negative/positive 2.88 (0.58–14.22) 0.195 
 SBEM  Negative/positive 2.17 (0.59–7.822) 0.239 







Isolated tumour cell detection in BM by means of immunocytochemical staining has been 
shown to be an independent prognostic factor in early breast cancer (Pantel and Alix-Panabieres 
2007; Braun et al. 2005; Wiedswang et al. 2003). ICC has been considered the gold standard for 
ITC detection and objective criteria for the evaluation of stained cells has been developed (Borgen 
et al. 1999). Reverse transcription (RT)-PCR has been used to indirectly detect tumour cells 
through the expression of epithelial or breast cancer-associated mRNA transcripts in BM, blood 
and other compartments. Although RT-PCR has been considered more sensitive than antibody-
based techniques very few studies have compared the detection rates and diagnostic accuracy of 
both methodologies (Schoenfeld et al. 1997; Lambrechts et al. 1999; Slade et al. 1999; Ring et al. 
2005; Benoy et al. 2004) in BM aspirate. Moreover, different markers have been evaluated in ITC 
by RT-PCR in breast cancer, and conflicting results about sensitivity and specificity have been 
reported (reviewed in Lacroix 2006). 
 
In our study we have evaluated for the first time the diagnostic accuracy of SBEM as a 
potential marker for BM micrometastasis in breast cancer. RT-PCR assay for detection of SBEM 
mRNA was compared with ICC with AE1/AE3 antibody in paired samples obtained from the BM 
of breast cancer patients. SBEM-specific transcript was found in 26% of patients, and the detection 
rate was similar to the percentage of patients with ITC detected, using ICC (24%). However, 
concordant results for both tests were found in 66%. Our results are comparable to those 
previously reported. Slade et al. (1999) reported a concordance of only 50% between ICC (based 
in CK staining) and quantitative RT-PCR for CK-19 mRNA when analysing BM samples of 
primary breast cancer patients. Benoy et al. (2004) compared the detection rates of ICC based in 
CK staining with RT-PCR in BM in a subgroup of 20 metastatic breast cancer patients. 
Concordances of 75 and 70% for CK-19 and hMAM were found respectively. 
 
It has been suggested (Schoenfeld et al. 1997) that some of CK positive cells were not viable or 
that they were dormant with low metabolic activity as defined by their inability to synthesise 
mRNA. In fact a single marker to detect and quantify ITC in BM or other samples might lead both 
to false-negative and false-positive analyses. Moreover and due to the low number of ITC usually 
present in BM and sensitivity of both methods of detection a stochastic effect and sampling errors 
cannot be ruled out (Slade et al. 1999). 
 
A previous work (Woelfle et al. 2003) had shown that BM micrometastases are associated to a 
specific transcriptional signature. Lower expression (at mRNA and protein level) of luminal CKs 
(CK8, CK18 and CK19) has been found in primary breast tumours with BM micrometastasis. It 
could be argued that a fraction of disseminated tumour cells in these patients might show a 
negative CK phenotype and missed in ICC detection. In addition, recent studies have clearly 
demonstrated that isolated and micrometastatic tumour cells included a remarkably heterogeneous 
population (Klein et al. 2002; Gangnus et al. 2004; Watson et al. 2007). Loss of luminal CKs and 
over expression of vimentin suggest that ITC have acquired an epithelial to mesenchymal 
transition phenotype (Willipinski-Stapelfeldt et al. 2005). We hypothesized that SBEM RT-PCR 
assay could detect a different population of disseminated tumour cells in BM than those detected 
in a CK-based assay. 
 
Variability in SBEM mRNA expression levels was identified among different human breast 
cancer cell lines tested in our previous study (Ayerbes et al. 2008). In mammary tissues, including 
breast cancer, SBEM expression has been shown to be restricted to luminal epithelial cells (Allinen 
et al. 2004). Although SBEM expression has been found in the ER-positive, well-differentiated, 
“luminal epithelial-like” breast cancer cell lines (Lacroix and Leclercq 2004), other studies have 
shown SBEM gene expression, as assessed by RT-PCR, in more than 90% of primary or metastatic 
breast cancers (Miksicek et al. 2002; Colpitts et al. 2002; Brown et al. 2006). In a small subset of 
primary breast tumours Skliris et al. (2008) have recently shown that SBEM mRNA was detected 
by RT-PCR in all cases. Furthermore, there was a significant correlation between SBEM protein 
expression (determined by immunohistochemistry) and SBEM gene expression (determined by 
RT-PCR and by Northern blot analysis). 
  
In our study, the detection of SBEM transcript in the BM of patients with breast cancer was 
significantly correlated with known clinicopathological prognostic factors. SBEM mRNA in BM 
aspirates were significantly associated with the presence of clinically active disease (47%, 
P = 0.021) and tumours with positive hormonal receptors (36.7%, P = 0.035). In addition, 
association with Her2/neu over-expression (44.4%, P = 0.051) was close to significance level. A 
previous report has shown significant association between Her2/neu determined by IHC and 
increasing amounts of SBEM mRNA (Lacroix and Leclercq 2004) in breast tumours. Using an in 
silico approach (Ayerbes et al. 2008) we have analysed the expression of SBEM tags in a series of 
human breast carcinomas SAGE libraries (n = 27). SBEM expression were quantified and 
correlated with the tag numbers of different molecular markers associated with breast cancer 
progression. Expression of SBEM was significantly correlated (Spearman’s rho) to Her2/neu 
expression (0.662; P = 0.000). 
 
Although it could appear paradoxical, in our study we found an association of SBEM mRNA in 
BM and low proliferating tumours, that was of borderline significance (36%, P = 0.067). Other 
authors have found no correlation between the presence of CK-positive cells in BM and Ki67 
staining in primary breast tumours (Schindlbeck et al. 2005). However, in a recent study that 
analysed SBEM protein expression in a large cohort (n = 300) of invasive breast cancers, negative 
association with Ki67 staining was found (Brown et al. 2006). Interestingly, most circulating and 
micrometastatic tumour cells do not express the proliferation antigen Ki67 and may therefore 
remain in the state of dormant cell-cycle arrest (Pantel et al. 1993; Muller et al. 2005). 
 
In our study, high tumour grade was significantly associated with ICC detection of ITC in BM 
as previously described (Braun et al. 2000, 2005). No correlations with other clinical or pathologic 
characteristic were found. Lack of association of BM status and other prognostic indicators could 
be dependent of different factors including stage of disease, study design and other methodological 
aspects. In stages I–III patients, the presence of CK positive cells in BM has been correlated with 
established prognostic factors, including pT and pN status (Braun et al. 2005; Wiedswang et al. 
2003) and hormonal receptor (Braun et al. 2005). However, Braun et al. (2000) found that the 
incidence of BM micrometastases was similar in patients with lymph-node metastasis and those 
without it and failed to detect an association between hormonal receptor status and positive CK 
staining in BM. In addition, in a recently published paper Bidard et al. (2008a) found that ITC 
detection in BM, using CK antibodies and specific morphologic features, did not correlate with 
any of the patient’s clinical or pathologic characteristics. Furthermore, in patients with 
locoregional and distant recurrent breast cancer, the presence of CK positive cells in BM at the 
time of relapse was not correlated with any of the clinical characteristics at the time of primary 
diagnosis (Janni et al. 2000). 
 
In order to explore the clinical significance of the detection of SBEM mRNA in BM in our 
series of breast cancer patients, we correlated the RT-PCR results and breast cancer progression. 
Breast cancer progression was found in six patients (40%) with SBEM mRNA in BM but only in 
two patients (13.3 %) with CK positive cells in BM. Diagnostic accuracy for SBEM RT-PCR for 
breast cancer progression was estimated in 68% (95%CI 53.2–80%). In addition, Kaplan–Meier 
survival analysis (Fig. 2) suggests a reduced time for breast cancer progression (TTP) among the 
SBEM mRNA BM positive patients, although this was not significant (log-rank test, P = 0.150). 
Prognostic impact for ITC in BM in breast cancer has shown to be dependent of several 
factors, including stage of disease, detection method (Bidard et al. 2008b) and molecular subtypes 
of breast cancer (Naume et al. 2007). Clearly, to ascertain a clinical utility, if any, for SBEM 
mRNA as a marker for ITC detection, a large study with homogeneous patient cohort and adequate 
sampled size is needed. 
 
However when we analysed TTP stratifying according to different prognostic factors, presence 
of SBEM in BM defines poor-prognosis groups adjusting for grade or hormone receptor status 
(Fig. 2). Tumour grade has been a highly valuable prognostic factor for breast cancer, as high-
grade lesions are associated with significantly poorer clinical outcome (Soerjomataram et al. 
2008). In addition, distinct transcriptional signatures had been found to be associated with 
different tumour grades (Ma et al. 2003). Patients with HR-negative breast cancer experienced 
relapse and progression more often than those with HR-positive tumours during the first 5 years. 
This is not surprising, taking into account the differences in genetic profiles between HR-negative 
and HR-positive tumours. In line with this, Ignatiadis et al. (2007) have recently analysed the 
prognostic significance of cytokeratin19 mRNA detection in blood in early breast cancer patients 
according to the molecular subtype. They found that CK-19 mRNA in blood was an independent 
prognostic factor for disease-free survival and overall survival only in patients with ER-negative 
tumours. 
Conclusions 
Small breast epithelial mucin might represent a suitable marker for molecular detection of ITCs 
in BM in breast cancer patients. However, and when we considered the different transcriptional 
molecular profiles of breast cancer, a multi-marker and quantitative approach could obtain a higher 
efficacy. Analysis of prognostic value for SBEM mRNA-based assay should take the heterogeneity 
and different molecular subtypes of breast cancer into account. 
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